A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19

A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19

Summary: Background: Current available therapeutic options for Coronavirus Disease-2019 (COVID-19) are primarily focused on treating hospitalized patients, and there is a lack of oral therapeutic options to treat mild to moderate outpatient COVID-19 and prevent clinical progression. Raloxifene was...

Full description

Bibliographic Details
Main Authors: Emanuele Nicastri, Franco Marinangeli, Emanuele Pivetta, Elena Torri, Francesco Reggiani, Giuseppe Fiorentino, Laura Scorzolini, Serena Vettori, Carolina Marsiglia, Elizabeth Marie Gavioli, Andrea R. Beccari, Giuseppe Terpolilli, Maria De Pizzol, Giovanni Goisis, Flavio Mantelli, Francesco Vaia, Marcello Allegretti
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:EClinicalMedicine
Subjects:
Raloxifene
COVID-19
SARS-CoV-2
Estrogen
Selective estrogen receptor modulator (SERM)
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022001808

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022001808

Similar Items